Stock Comparison

LLY vs SMMT

Eli Lilly and Co vs Summit Therapeutics Inc

Who's the better investment? Let's break it down.

The Verdict

SMMT takes this one.

It's not even close. SMMT outscores LLY by 8.2 points. That's a significant gap in our deep value framework.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

SMMT

Summit Therapeutics Inc

8.7

out of 10

Hidden Gem

Want to compare any two stocks?

Valuation

LLY

Metric

SMMT

$965.0B

Market Cap

$14.3B

52.6

P/E Ratio

Lower may indicate better value

-10.4

N/A

Forward P/E

0.0

40.5

Price/Book

74.7

N/A

EV/EBITDA

0.0

Profitability & Growth

LLY

Metric

SMMT

N/A

Profit Margin

0.0%

N/A

Gross Margin

0.0%

N/A

Operating Margin

0.0%

N/A

Return on Equity

-292.5%

N/A

Return on Assets

-152.9%

N/A

Revenue Growth

0.0%

N/A

EPS

$-1.25

Financial Health

LLY

Metric

SMMT

N/A

Debt-to-Equity

Lower = less leverage

0.0

N/A

Current Ratio

Above 1.0 is healthy

0.0

N/A

Beta

Lower = less volatile

-1.4

58.0%

Dividend Yield

None

Risk Comparison

LLY

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

SMMT

Overall

Aggressive

Financial

Medium

Market

Medium

Competitive

High

Execution

High

Regulatory

High

Competitive Moat

LLY

Rating

🛡️ Wide

Trend

📈 Expanding

Intangible Assets/IPBrand PowerCost AdvantagesSwitching Costs

SMMT

Rating

🛡️ Narrow

Trend

📈 Expanding

Intangible Assets/IP (patent protection for ivonescimab)

Investment Thesis

LLY0.5/10

Eli Lilly is a pharmaceutical leader with a multi-decade growth runway, primarily driven by its innovative GLP-1 franchise (Mounjaro/Zepbound) and a robust pipeline in Alzheimer's and other high-demand therapeutic areas. Its strong R&D, manufacturing scale, and expanding market share position it for sustained, above-average growth within the healthcare sector, making it a core holding for long-ter...

Full LLY Analysis

SMMT8.7/10

Summit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it na...

Full SMMT Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achieving a 10x return ($10 trillion+) within a 3-5 year timeframe fundamentally unrealistic. The major gr...

Full LLY Analysis

SMMT8.7/10

Summit Therapeutics continues to hold significant 10x growth potential, primarily driven by its lead asset, ivonescimab, targeting the large US/EU non-small cell lung cancer (NSCLC) market. The bispecific mechanism provides a strong competitive advantage, and key regulatory milestones like the PDUFA date in November 2026 and HARMONi-3 interim data in Q2 2026 serve as major catalysts. The company maintains a robust cash position and positive free cash flow, supporting its clinical development. Ho...

Full SMMT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.